0001144204-18-007711.txt : 20180213
0001144204-18-007711.hdr.sgml : 20180213
20180213133326
ACCESSION NUMBER: 0001144204-18-007711
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20171231
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
EFFECTIVENESS DATE: 20180213
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovaQuest Capital Management, L.L.C.
CENTRAL INDEX KEY: 0001729264
IRS NUMBER: 273425707
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-18424
FILM NUMBER: 18601780
BUSINESS ADDRESS:
STREET 1: 4208 SIX FORKS ROAD
STREET 2: SUITE 920
CITY: RALEIGH
STATE: NC
ZIP: 27609
BUSINESS PHONE: 919-459-8616
MAIL ADDRESS:
STREET 1: 4208 SIX FORKS ROAD
STREET 2: SUITE 920
CITY: RALEIGH
STATE: NC
ZIP: 27609
13F-HR
1
primary_doc.xml
13F-HR
LIVE
false
false
false
0001729264
XXXXXXXX
12-31-2017
12-31-2017
false
NovaQuest Capital Management, L.L.C.
4208 Six Forks Road
Suite 920
Raleigh
NC
27609
13F HOLDINGS REPORT
028-18424
Y
The securities listed in the information table are held by NovaQuest Pharma Opportunities Fund III, L.P. ("Fund III"), NovaQuest Pharma Opportunities Fund IV, L.P., and NovaQuest Pharma Opportunities Fund IV (Parallel), L.P. ("Fund IV Parallel" and collectively with Fund III and Fund IV, the "NovaQuest Funds"), as applicable. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, or for any other purpose, that NovaQuest Capital Management, L.L.C. ("NovaQuest Capital") or any other person exercises investment discretion with respect to the securities listed herein or is a member of, or is otherwise affiliated with, such a group with respect to such securities. Reference is made, where relevant, to reports filed under Sections 13(d), 13(g) and 16(a) of the Exchange Act for additional information with respect to such beneficial ownership and/or pecuniary interest of securities held by the NovaQuest Funds. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Exchange Act and the rules thereunder, or for any other purpose, that NovaQuest Capital or any other person is the beneficial owner of any securities held by the NovaQuest Funds. With respect to the entities listed as Other Managers on this Form 13-HR and accompanying Information Table, NQ HCIF General Partner, L.P., the general partner of Fund III ("Fund III GP"), has the authority to vote securities directly owned by Fund III, and NQ HCIF GP, Ltd., the general partner of Fund III GP, has the authority to direct Fund III GP as to such voting.
John L. Bradley, Jr.
Manager
919-459-8622
/s/ John L. Bradley, Jr.
Raleigh
NC
02-13-2018
3
3
125726
2
0001506260
028-16648
NovaQuest Pharma Opportunities Fund III, L.P.
3
0001598327
028-16646
NQ HCIF General Partner, L.P.
4
0001598203
028-16645
NQ HCIF GP, Ltd.
INFORMATION TABLE
2
infotable.xml
REVANCE THERAPEUTICS, INC.
COM
761330109
110705
3096650
SH
DFND
2, 3, 4
0
0
3096650
MYOVANT SCIENCES LTD.
COM
G637AM102
13272
1050000
SH
DFND
2, 3, 4
0
0
1050000
MYOVANT SCIENCES LTD.
COM
G637AM102
1749
138361
SH
DFND
0
0
138361